Clinical trial · Observational
5 Years Follow-up With Adjuvant Therapy for Women With Breast Invasive Carcinoma
5 Years Follow-up in the Lorraine Institute of Oncology With Adjuvant Therapy for Women With Breast Invasive Carcinoma
NCT02791750CI-TRIAL-00034213HACAMIcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Non-persistence to adjuvant hormonal therapy for breast cancer at 5 years decrease its efficacy. The objective of this study is to know the women experience (persistence, treatment changes, quality of life) and its determinants, in a french population.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| questionnary of quality of life | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational
- description
- Patients followed for a medical consultation in the Institut de Cancérologie de Lorraine at 5 years of the beginning of an adjuvant hormonal therapy.
- interventionNames
- Other: questionnary of quality of life
Primary outcomes (1)
- measure
- Factors associated with persistence to hormone therapy for breast cancer
- timeFrame
- 1 day
- description
- Women will be classed as persistent if they don't discontinue or abandon hormone therapy during the 5 years after the introduction of the medication. The information will be recorded thanks to a self-questionnary fulfilled the inclusion day. The baseline characteristics will be compared between persistent women and non-persistent women.
Secondary outcomes (4)
- measure
- Comparison of the quality of life
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients following-up in the Lorraine Institute of Oncology at 5 years of the beginning of an adjuvant hormonal therapy * Women with breast invasive carcinoma positive-RH and indication of adjuvant hormonal therapy * Adult patients * Being capable and agree to follow the study procedure * Patients informed and non-opposed * Covered by social security Exclusion Criteria: * History of other cancer except basal cell carcinoma * Patients with breast invasive carcinoma negative-RH * Synchronous metastases * Relapsed * Previous adjuvant hormonal therapy * Men * Patients with guardianship
References
Publications (0)
Data not yet available
No reference posted for this study.